Resultado de búsqueda
30 de jun. de 2017 · This collection of one hundred pieces of writing represents years five and six of Henry’s employment at the LA Weekly. The fact that he has not been canned perhaps causes mild astonishment. Why do they keep him on?
- (41)
- Paperback
14 de ene. de 2023 · Before the Chop II: LA Weekly Articles 2013-2014, 2015, 2.13.61 Publications. Before the Chop III: LA Weekly Articles 2014-2016, 2017, 2.13.61 Publications. Before the Chop IV: LA Weekly Articles (And More) 2012-2018, 2018, 2.13.61 Publications. Stay Fanatic!!! Vol. 1: Hectic Expectorations For the Music Obsessive, 2019, 2.13.61 ...
4/5: I like Rollins' writing style a lot these days, and I was afraid the column format would constrain him a bit, but my fears were mostly groundless--this read a lot like his books of journal entries, which are my favorites of his. The whole "unedited versions" gimmick might be a little much since there are times when obvious grammatical errors and even outright typos make it into the ...
- Drew
Before the Chop: LA Weekly Articles 2011-2012, 2013, 2.13.61 Publications ISBN 978-1880985533; A Grim Detail: Destination Documentation and Multi-Continental Self Examination 2009-2010, 2014, 2.13.61 Publications; Before the Chop II: LA Weekly Articles 2013-2014, 2015, 2.13.61 Publications
16 de abr. de 2019 · Abstract. Bortezomib is a dipeptidyl boronic acid that selectively inhibits the ubiquitin proteasome pathway, which plays a role in the degradation of many intracellular proteins. It is the first-in-class selective and reversible inhibitor of the 26S proteasome, with antiproliferative and antitumor activity.
The identification of the CD20 antigen in 1979 was the first step in what would become a therapeutic milestone opening the use of immunotherapy in hematological diseases. This protein is expressed on the surface of developing B cells, but not the early progenitors or mature plasma cells. In 1997, rituximab was approved by the Food and Drug ...
12 de feb. de 2024 · The CHOP regimen (cyclophosphamide, doxorubicin, vincristine, prednisone) has been the standard treatment of diffuse large B-cell lymphoma (DLBCL) since its introduction in the 1970s. 1, 2 In the early 2000s, the monoclonal anti-CD20 antibody rituximab was added to the CHOP regimen, leading to substantial improvement of 5-year disease-specific survival. 3, 4 Five-year relative survival rates ...
